The FTC Is Suing Hims & Hers Health—Here's Why Investors Shouldn't Panic Hims & Hers Health shares have rallied despite an FTC lawsuit over data sharing and billing practices, as weight-loss drug partnerships and Wall Street's cautious Hold rating shape the stock's outlook ahead of Q2 earnings.
Bearish Pressure Is Building Around These 3 Stocks Hims & Hers Health and QXO face heavy short interest amid dilution and loss concerns, while KLA has slid nearly 40% since June as AI-driven chip spending fears grip semiconductor stocks.
3 Beaten-Down Stocks With GLP-1 Exposure to Buy and Hold They may profit from the rapidly growing GLP-1 market in very different ways.
Where Will Novo Nordisk Stock Be in 3 Years? Trailing a powerful competitor, Novo Nordisk could stay firmly in second place for a good while.
3 Absurdly Cheap Dividend Stocks to Buy With $1,000 Right Now With yields like this, these undervalued tickers aren't apt to remain this cheap forever.
Novo Nordisk's Dividend Story Is Changing -- Here's What Investors Are Missing Novo Nordisk is offering an attractive 3.5% yield backed by a business where volume is the new focus.
The Most Overlooked Reason Eli Lilly Stock Keeps Surging -- and It Has Nothing to Do With Weight Loss There's a good reason why investors are focused on Eli Lilly's GLP-1 business, but there's more going on at the company.
This GLP-1 Stock Could Double by 2030. Here's Why Investors need to ask tough questions before initiating a position in this biotech company.
2 Beaten-Down GLP-1 Stocks to Buy on the Dip Don't wait until clinical milestones send their share prices soaring.
3 Dividend Stocks That Are No-Brainer Buys Heading Into the Second Half of 2026 This is the list for you if you are looking for dividend stocks with attractive yields and well-supported dividends.
Is Pfizer on Track to Launch Its Next Lipitor -- This Time in the Weight-Loss Market? So far, Pfizer has been an also-ran in the GLP-1 race, but that could change if its long-acting weight-loss medication takes off.
